Introduction
The neoplastic transformation of fully differentiated glia has been previously implicated as the principal cause of gliomagenesis [1] . This idea is supported by the findings of prior studies reporting that glioma formation from normal human astrocytes could be achieved via the ectopic expression of a number of oncogenes-SV40 T/t-Ag, H-ras, and hTERT [2] . Because adult glial cells are generally believed to be the only cells that divide in the postnatal brain, they may represent a vulnerable target for neoplastic transformation by a variety of oncogenic mutations, including p53, PTEN, NF1, EGFR, ERBB2, and RB1, which are frequently shown to be mutated in brain cancers, as previously demonstrated in mouse model studies [3, 4] . However, the results of recent studies have shown that neural stem cells and glial progenitor cells, both of which retain their proliferative capacity, were detected in multiple regions of the postnatal brain [1, 5, 6] . Therefore, classic theories regarding the cells of origin of brain cancers must be reconsidered. In this regard, some brain cancersparticularly glioblastoma and medulloblastoma, which frequently occur in cases of pediatric brain cancer-have reportedly been derived from neural stem cells [7, 8] . The inactivation of several tumor suppressors, including p53, NF1, and PTEN in neural stem/precursor cells located within the subventricular zone (SVZ), results in the formation of malignant astrocytoma [9] . The results of several previous studies have shown that neural stem/ progenitor cells may prove more susceptible to malignant transformation [7, 9] .
Interestingly, human somatic cells, including astrocytes, have generally been considered to be more resistant to oncogenic transformation than murine somatic cells, owing to their intrinsic tumor suppressive mechanisms [10] . Human somatic cells require at least three genetic events for cellular transformation: immortalization, self-sufficient growth control, and the abrogation of the tumor-suppressive mechanism [11] . The tumor-suppressive mechanism, which is frequently governed by the p53 tumor suppressor, carries out a pivotal function in preventing the transformation of normal cells. In the majority of human gliomas, the disruption of the tumor-suppressive mechanism (the p53 and Rb pathway) in parallel with abnormally active signals (Ras and telomerase) has been demonstrated [12] . It has also been shown that a simultaneous alteration satisfying three genetic events (immortalization, self-sufficient growth control, and abrogation of the tumor-suppressive mechanism) is required for the transformation of human astrocytes [2] . Therefore, the abrogation of the p53-dependent tumor suppressive mechanism is indispensible in the transformation occurring in response to a variety of oncogenic stimuli [13] [14] [15] .
In this study, we demonstrate that the serial introduction of v-myc and H-Ras was sufficient for the transformation of hfNSCs, which evidenced some characteristics of cancer stem cells. F3.Ras cells induced the formation of peripheral neuroepithelioma (PNET)-like cancer masses in nude mouse brains. Furthermore, the molecular mechanism involved in hfNSCs transformation was linked to defective p53 responses in v-myc expressing hfNSCs.
Materials and Methods

Generation of v-myc Expressing Human Fetal Neural Stem Cells
The amphotropic replication-incompetent retroviral vector pLSN.v-myc was used to infect human brain cells isolated from fetal brains at 15 weeks of gestation. Permission to use the fetal tissues was granted by the Clinical Research Screening Committee involving Human Subjects of the University of British Columbia. The pLSN.v-myc vector was generated using the ecotropic retroviral vector encoding for v-myc, in a fashion similar to that described previously for the generation of hfNSC lines [16] [17] [18] . The PA317 amphotropic packaging cell line was infected with the pLSN.v-myc vector, and successful infectants were selected and expanded. Supernatants generated from the PA317 producer cell line (PASK1.2) harbored replicationincompetent retroviral particles bearing an amphotropic envelope which efficiently infected the hfNSCs, as indicated by the observed G-418 resistance. Two milliliters of culture supernatant from the packaging cell line and 8 μg/ml of polybrene were added to the brain cells in six-well plates and incubated for 24 h at 37°C. The medium was subsequently replaced with fresh growth medium; the infection procedure was repeated 24 and 48 h later. 72 h after the third infection procedure, the infected cells were selected for 14 days with G-418 (200 μg/ml), and large clusters of cells were individually isolated and grown in dishes coated with poly-L-lysine. Individual clones (n=3) were again selected via limited dilution and further propagated. The resultant v-myc-expressing hfNSCs were referred to as HB1.F3 and were used in the present study. F3 NSCs were cultivated in a serum-free medium (DM4) consisting of DMEM with high glucose containing 10 μg/ml insulin, 10 μg/ml transferrin, 30 nM sodium selenate, 50 nM hydrocortisone, and 0.3 nM T3. the DM4 was supplemented with recombinant human basic fibroblast growth factor (bFGF, 10 ng/ml; PeproTech, Rocky Hill, NJ) during routine feeding. All chemicals except bFGF were purchased from Sigma-Aldrich (St. Louis, MO). F3 NSCs were also maintained in DMEM medium supplemented with 10% (v/v) fetal bovine serum (FBS) with 20 μg/mL of gentamycin (Sigma) at 37°C in a humidified 5% CO 2 incubator. 5 were incubated with the virus-containing medium for 48 h, in the presence of 4 μg/ml of polybrene (Sigma). The infection procedure was repeated 24 and 48 h later. 72 h after the third infection procedure, infected cell populations were selected via the addition of 0.5 μg/ml of puromycin to the medium. Three large colonies of cells were individually isolated and grown via limited dilution and further propagated.
Generation of Cancerous
Reagents
Primary antibodies against Nestin (10c2: sc-23927), HRas (c-20: sc520), cyclin B1 (GNS1: sc-245), cyclin E (sc-198), ki-67 (H-300: sc-15402), β-actin (sc-47778), and GFAP (sc-9973) were obtained from Santa Cruz Biotechnology. Primary antibodies against phosphorylated Rb (pRb, ser795: # 9301), phosphorylated Akt (pAkt, ser473: # 4060X), phospho-Histone H3 (Ser10: # 9706), phosphorylated p42/44 (ppERK, # 9106), and E-cadherin (# 4065) were acquired from Cell Signaling Technology (Danver, MA). Primary antibodies against Snail (# ab17732), and Sox2 (# ab15830) were acquired from Abcam (Cambridge, MA). Secondary antibody Alexa 594-conjugated goat anti-mouse IgG was purchased from Molecular Probes (Eugene, OR), and Cy2-conjugated goat anti-rabbit IgG from Jackson ImmunoResearch (Wes Grove, PA).
Generation of Tumorspheres
Tumorspheres were generated by culturing F3 and F3.Ras cells in DMEM/F12 supplemented with 2% B27, 8 mM HEPES, 100 U/mL of penicillin, 100 μg/mL of streptomycin and 20 ng/mL of bFGF (invitrogen, Carlsbad, CA) for 7 days.
Immunoblotting
The cells were washed twice in ice-cold phosphate buffered saline (PBS), lysed with 300 μl of tissue lysis buffer, and centrifuged for 10 min at 14,000 rpm (to clarify the lysates). Approximately 20 μg of total proteins were separated via SDS-PAGE. The proteins were then transferred to PVDF membranes, blocked for 1 h with 5% nonfat dry milk in Tris-buffered saline (TBS) with 0.1% Tween-20 (TBS-T), and incubated for 1 to 16 h with the appropriate primary antibodies in TBS containing 1% BSA solution. The membranes were subsequently washed several times in TBS-T solution and incubated with HRP-conjugated secondary antibodies (0.1 μg/ml; Jackson ImmunoResearch Laboratories, West Grove, PA). Immunoreactivity was detected using an enhanced chemiluminescence detection system (Amersham Biosciences, Piscataway, NJ).
Immunofluorescence
Cells cultivated on round glass coverslips were fixed with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.2) for 10 min, and subsequently permeabilized for 5 min with 0.1% Triton X-100 in PBS. The fixed cells were incubated in TBS containing 3% BSA (for blocking) for 30 min, followed by 1 h of incubation with specific primary antibodies. The cells were washed 3 times in TBS-T solution, then incubated with Alexa 594-conjugated goat anti-mouse or Cy2-conjugated goat anti-rabbit IgGs. Cellular nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI, 0.2 μg/mL) in PBS.
Immunohistochemistry
The tumor tissues from mice injected dermally with F3.Ras and U373 human glioma cells were fixed in phosphatebuffered 10% formalin and the tissue samples were embedded in paraffin. The paraffin sections were deparaffinized, rehydrated, and subjected to citrate-based antigen retrieval. Primary antibodies specific for GFAP, Nestin, ki-67, and phospho-Histone H3 were used. The secondary antibodies used were Alexa 594-conjugated goat anti-mouse or Cy2-conjugated goat anti-rabbit IgGs for immunofluorescence, and ABC kits (Vector Laboratory) for HRP staining. The sections were also stained with hematoxylin and eosin (H&E) for histopathological analysis.
RNA Isolation and Quantitative Real-Time PCR Analysis
Total RNA was extracted from the cells using TRIzol Reagent (Invitrogen), followed by treatment with DNase I, in accordance with the manufacturer's instruction. Trizol was removed via the addition of chloroform, and mRNA was precipitated with isopropanol. The RNA precipitates were washed with 75% ethanol. The quantity and purity of RNA were assessed by optical density measurements at 260 nm and 280 nm using an UV spectrometer, and the integrity of the RNA was confirmed via agarose gel electrophoresis. Gene-specific primers were designed to amplify human Sox2 (forward: 5′-ATGCACCGCTAC GACGTGA-3′, reverse: 5′-CTTTTGCACCCCTCCCATTT-3′); hNestin (forward: 5′-AGAAGAGGACCAGAGTATTGT GAG-3′, reverse: 5′-TCCGTCGCTGTT GAG TCTC-3′); human ABCG2 (forward: 5′-TTAAGTGGAAACTGCT GCTTT AGGT-3′ , reverse: 5′ -TCGGTCTTAAC CAAAGGCTCA-3′) and the housekeeping gene GAPDH. All amplifications were conducted in a pre-mixture (20 μl) containing 500 nmol/l of gene-specific primers, and 2 ml of template, under the following conditions: denaturation at 95°C for 1 min, followed by 30 cycles of 95°C for 30 s, 58°C for 30 s, and 72°C for 30 s, with a final extension at 72°C for 5 min. For PCR validation, amplified products were separated on 2% agarose gels and visualized by ethidium bromide staining. p53 dependent gene expression was demonstrated by RT 2 profiler PCR array human p53 Signaling Pathway as described by the manufacturer. The reactions were carried out in an Applied Biosystems 7500 Fast-Real Time PCR System (Applied Biosystems, Foster City, CA).
Soft Agar Assay
Each well of a 6-well plate was coated with 3 ml of bottom agar mixture (DMEM, 10% FBS, and 0.6% agar). After the bottom layer solidified, 2 ml of top agar mixture (DMEM, 10% FBS, and 0.3% agar) containing 5 x 10 5 cells was added to each well, and the cultures were incubated at 37°C in a 5% CO 2 atmosphere. Every 5 days, normal growth medium was layered gently over the cultures. Colony formation was monitored daily using a light microscope. Colonies formed in soft agar were photographed with a digital camera after 14 days of incubation.
Fluorescent In Situ Hybridization (FISH)
FISH was conducted using two human chromosome-specific probes, LSI 21 (Spectrum Orange, Abbott Laboratories, Chicago, IL) and CEP18 (Spectrum Green, Abbott). Slides and probe preparation were carried out in accordance with the routine FISH protocol. Probe hybridization was conducted using a Hybrite system (Abbott) at 37°C for 16 h. After post-hybridization washing, the slide was counterstained with 4′6′-diamino-2-phenylindole dihydrochloride (DAPI). The FISH signals were captured with a Cytovision system v3.6 (Applied Imaging, London, UK).
Transplantation of Transformed Cells in Mouse Muscle and Brain
NOD/SCID male mice at 6 weeks of age were subcutaneously injected with 1×10 6 F3.pBabe or F3.Ras cells in the thigh muscle, and tumor appearance after 6 weeks was monitored. Tumor masses from the right thigh area injected with F3.Ras cells were isolated and processed for histology. The isolated tumor masses were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4), processed into paraffin sections, and stained with hematoxylin and eosin (H/E). The tumor tissue sections were immunostained with proliferation markers (phospho-Histone H3) and cell type-specific markers for astrocytes (GFAP), proliferation markers (Ki-67) and cell type-specific markers for neural stem cells (hNestin). In like manner, F3 and F3.Ras cells were injected intracerebrally into NOD/SCID mice. Paraffin sections prepared from the brains of the mice were processed for H/E, phospho-Histone H3, hNestin, GFAP, and Ki-67 staining.
Results
Generation of Human Neural Stem Cells Encoding v-myc and Ras
The stable expression of v-myc in hfNSCs exerted no distinct effect on cellular morphology or chromosome karyotyping compared to the parent hfNSCs (Fig. 1a , upper panels and Supplemental Figure. 1 ). Even after vmyc expression, levels of human Nestin (hNestin) or Sox2 expression were comparable to the parent hfNSCs, but not in the human dermal fibroblasts (hDFs) (Fig. 1a , bottom panels and right panels). Thereafter, v-myc-expressing hfNSCs (F3) cells were used for further genetic modification. The constitutively active form of H-Ras was expressed stably in F3 cells, generating F3.Ras cells. Unlike the F3 cells, which maintained the morphology of the parent hfNSCs, the F3.Ras cells were clearly morphologically altered (Fig. 1b) . The morphology of the F3.Ras cells was similar to the typical morphology of transformed cells (e.g. condensed cytoplasm, focus formation, and loss of contact inhibition) as reported elsewhere [19] . In order to validate the effects of H-Ras, the characteristic signals of H-Ras activation, including ERK and Akt activation, were evaluated via immunoblotting. As anticipated, both phosphorylated ERK and Akt were highly and constitutively activated in F3.Ras cells with stable H-Ras expression (Fig. 1c) . It has been relatively well established that ERK and Akt activations induced by mitogenic or oncogenic signals are responsible for accelerated proliferation compared to both F3 and F3.pBabe cells (left panel Fig. 1d ). The proliferation of F3.Ras cells is correlated with the upregulation of a variety of cell cycle regulators, including cyclin B1 and cyclin E, and subsequent Rb hyperphosphorylation (right panel, Fig. 1d ). As an assay of cellular transformation, anchorage-independent growth was measured by the growth rate assessed on soft-agar. As compared to the E1a/Ras mouse embryonic fibroblast (MEF) used as a positive control, the numbers of F3.Ras colonies grown on soft-agar were comparable to those of E1a/Ras MEF, thereby indicating that the F3.Ras cells were indeed transformed (Fig. 1e) .
F3.Ras Cells Retain Cell Type-Specific Markers for Neural Stem Cells
F3 cells express characteristic phenotypes of hfNSCs, and also express characteristics NSC markers such as Fig. 1 v-myc (Fig. 1a, right panel) and the ATP-binding cassette transporter (ABCG2) [20] . We therefore attempted to determine whether the introduction of H-Ras to the F3 cells altered the neural stemness of the F3 cells. In order to answer this question, we determined the levels of hNestin and SRY box-containing gene 2 (Sox2), both of which are utilized extensively for the identification of neural stem/ progenitor cells [21] . As shown in Fig. 2a , both hNestin and Sox2 were clearly stained in both F3 and F3.Ras cells, but not in human bone marrow mesenchymal stem cells (hMSCs) (Fig. 2a) . Similarly, the mRNA of Sox2 and hNestin were expressed in both F3 and F3.Ras cells (Fig. 2b) . Interestingly, the levels of Sox2 and hNestin protein in F3.Ras cells appeared to have moderately increased relative to what was observed in the F3 cells (Fig. 2c) . Therefore, the F3.Ras cells apparently retain neural stemness characteristics similar to those of F3 cells, even after cellular transformation. Under sphere culture conditions, F3.Ras cells formed larger-sized spheres than the control F3 cells (Fig. 2d) .
F3.Ras Cells Share Characteristics of Cancer Stem Cells
We subsequently attempted to determine whether or not the F3.Ras cells share any properties in common with neural cancer stem cells isolated from adult or pediatric brain cancers, as has been reported in a number of previous studies [22] [23] [24] . In this comparison, we initially compared the levels of ABCG2, one of the ABC transporters, which is expressed abundantly in brain tumor stem cells [25, 26] . The levels of ABCG2 mRNA were markedly upregulated in F3.Ras cells (Fig. 3a) . Recently, aldehyde dehydrogenease 1 (ALDH1) was implicated as a novel cancer stem cell marker that might prove useful in the identification of a variety of stem-like cancer cells from the breast [27] , lung [28] , colorectal region [29] , and head and neck [30] cancers, as well as circulating tumor cells [31] . As anticipated, the levels of ALDH1 mRNA were induced significantly in F3.Ras (Fig. 3b) . Next, the levels of E-cadherin protein were determined in order to evaluate the epithelial mesenchymal transition (EMT), which has been identified as either the cause or consequence of [32] [33] [34] [35] . As is shown in Fig. 3c , the F3.Ras cells evidenced a marked loss of E-cadherin relative to the F3 cells, which indicates that the F3.Ras cells had undergone EMT. Interestingly, Snail, which is known to be responsible for the suppression of E-cadherin expression, was upregulated to a significant degree in F3.Ras cells (Fig. 3c middle  panel) . In sequence, F3 and F3.Ras cells is comparable to fetal NSC, U87 glioma cell line, and U87 sphere stem-like cancer cells. As predicted, c-myc expression was found in both F3 and F3.Ras cells since F3 cells were generated by introducing v-myc to the fetal neural stem cells (fNSCs). Strong H-Ras expression was found in only in F3. Ras cells. Consistently, strong phospho-Rb level was distinct in F3.Ras indicating active proliferative potential. Of note, p53 protein level was high in both F3 and F3.Ras cells that were derived by v-myc expression (Fig. 3d) . Considering p53 protein stabilization by c-myc and p53 dependent stress respons, high protein level of p53 in both F3 and F3.Ras cells may result from expression of v-myc. However, in unidentified reason, F3 and F3.Ras lost p53 dependent transcriptional activity (Figs. 4, 5 and 6 ) and the molecular mechanism to govern the unexpected p53 response is currently under investigation.
F3.Ras Cells Develop Central Glial Tumor in Mice
We then attempted to determine whether F3.Ras cells could induce tumor formation under in vivo conditions. Six weeks after the intramuscular injection of F3 cells into the right thigh and F3.Ras cells into the left thigh of the experimental mice, the left thigh area (indicated by straight line, Fig. 4a ) into which the F3.Ras cells had been injected developed tumors. Following the surgical extraction of the tumor mass, a clear difference was detected between the tumor masses originating from the F3 and F3.Ras cells (Fig. 4a, bottom panel) . As is shown in Fig. 4b , tumor formation in the mice injected with F3.Ras was obvious. The gross appearance of the F3.Ras-induced tumor was that of a soft, polypoid tumor, composed of undifferentiated or poorly differentiated neuroepithelial cells. The microscopic appearance of the tumor is that of a cellular tumor composed of small uniform cells with scant fibrillar cytoplasm and oval configured nuclei with frequent mitotic populations. Tumor cells are arranged in lobules that harbor scattered rosettes (Fig. 4b) . In order to further characterize the tumor tissue in detail, immunohistochemical studies have been carried out using antibodies including Ki-67, hNestin, and GFAP. A small portion of the entire tumor tissue tested positive for hNestin, thereby indicating that the neural stemness of injected F3.Ras cells may have been lost during cancer development. Cells positive for Ki-67, a proliferation antigen, were also relatively sparse, indicating that only a small number of F3.Ras cells retained proliferation potential subsequent to cancer development (Fig. 4c) . These results are consistent with the immunohistochemical image, stained for the mitotic marker, phospho-H3. Only a few cells were positive for phospho-H3, which is consistent with the (Fig. 4d) . Unlike hNestin, which is expressed by only a small number of tumor cells, GFAP, which is widely employed as a cell-type specific marker for glial differentiation, was more broadly positive ( Fig. 4c and d) . By way of contrast, tumor tissues from injections of U373 human glioma cells consisted of GFAP and Ki-67 positive populations with no clear Nestinpositive cells (Supplemental Figure 2) . The results of fluorescent in situ hybridization (FISH) analysis with human probes demonstrated that the tumor tissue was derived from human cells into which the F3.Ras cells had been injected (Fig. 4e ). These results demonstrate that F3.Ras cells form glial tumors consisting largely of GFAP-positive glial cells, in addition to a minor population of undifferentiated hNestin-positive neural stem cells.
F3.Ras Cells Develop Brain Tumors in the Mouse Brain
After intracerebral injection of F3.Ras cells, highly cellular tumor cells were located within the large portion of the cerebral hemisphere (Fig. 5a and b) . These tumors were composed of undifferentiated or poorly-differentiated neuroepithelial cells. The tumor cells evidenced an ovoid morphology without prominent nuclei, and exhibited frequent mitoses. Geographic coagulative necrosis was also , and tumor appearance after 6 weeks was assessed. Tumor masses from the right thigh area injected with F3.Ras cells were isolated and processed for histologic analysis (right panel). b Tissues isolated from the tumor mass were stained with hematoxylin and eosin (H/E), and the tumors were identified. c Tumor tissues were immunostained with proliferation markers (phospho-Histone H3) and cell type-specific marker for astrocytes (GFAP). Bar indicates 100 μm. d Tumor tissues were immunostained with proliferation marker (Ki-67) and cell type-specific marker for neural stem cells (hNestin:). Lower panels are H/E staining images. e FISH with human chromosome probe on mouse tumor tissue (LSI21 for red, CEP18 for green). DAPI for nuclear counterstaining noted in these tumors. The tumor masses in the brains of the mice were immunostained with antibodies specific for human nuclear antigen (hNuA) in order to confirm that the tumor cells were of human origin. The tumor region was clearly distinguished by positive hNuA staining (Fig. 5c , bottom right panel). As in the cancer model from F3.Ras cells (Fig. 4c and d) , hNestin and GFAP were expressed in the tumor tissues, but MAP2 was not-thus indicating that the F3.Ras cells had undergone an asymmetric self-renewal to either cancerous stem cells (Nestin positive) or astrocytelike cells (GFAP positive), but not neurons (Fig. 5c and Supplemental figure 3) . It is worth noting that hNestinpositive cells were more numerous in the brains into which F3.Ras cells were transplanted than in thigh muscle tissues similarly injected with F3.Ras cells (Fig. 4c) .
Defective p53 Tumor-Suppressive Properties
Since normal primary human cells employ a variety of tumorsuppressive mechanisms and are resistant to oncogenic stresses such as H-Ras, the abrogation of tumor-suppressive mechanisms, particularly those involving p53, is regarded as a prerequisite for cellular transformation by H-Ras [10, 36] . In the case of F3.Ras cell generation, the parent v-mycexpressing hfNSC (F3) cells underwent oncogenic transformation via a single introduction of H-Ras in the absence of any further genetic modifications to abrogate p53; thus, it is conceivable that the F3 cells may possess a less active p53 tumor-suppressive mechanism. F3 and F3.Ras cells were subjected to a phospho-kinase profiler array in an effort to evaluate altered signaling as the result of the introduction of H-Ras. Taking into consideration the high levels of AKT phosphorylation (serine 473) and MEK1/2 phosphorylation (serine 218/222, serine 222/226) shown in the F3.Ras cells (iii, Fig. 6d ), the profiler array was validated. A high level of p53 phosphorylation, which is indicative of the activation or increased stability of p53, was demonstrated in the F3.Ras cell lysates (i: serine 46, ii: serine 15). These results demonstrate that the introduction of H-Ras to F3 cells triggered p53 phosphorylation, which further activates p53-dependent tumor-suppressive mechanisms. To monitor the altered profile of p53-dependent genes after H-Ras introduction, the F3 cells were subjected to a p53 signaling pathway Human nuclei (hNuA) staining conducted to show human cell-derived cancer area. Bar:100 μm. White box (right bottom panel) was enlarged at higher magnification PCR array [37] . Among 13 genes that tested positive on the array, 11 genes-including CDKN1A and NF1-were reduced significantly relative to the F3 cells even after H-Ras introduction ( Fig. 6b and Supplemental table. 1). In particular, the tumor suppressor gene NF1 encoding for neurofibromin 1 (Nf1), which is frequently suppressed or mutated in glioma or during gliomagenesis [38, 39] was detected at a significantly lower level after H-Ras introduction. These lowered Nf1 levels in F3.Ras cells were confirmed via immunoblotting analysis (Supplemental figure 4 ). Finally, we stimulated both F3 and F3.Ras cells with ultra-violet C (UVC) radiation and determined the Gadd45a mRNA levels, which corresponded closely with p53 transcriptional activity [40] . Similarly to the p53 null HCT116 cells, both F3 and F3.Ras cells failed to induce Gadd45α, whereas the p53 wild-type HCT116 cells induced Gadd45α mRNA after exposure to UVC radiation stress (Fig. 6c) . The protein levels of p21 in the F3 and F3. Ras cells following treatment with nutlin3 (a chemical inhibitor of mdm2, which causes p53 accumulation) were significantly lower than those detected in the HCT116 wt cells (Fig. 6d) . These results clearly indicate that F3 cells have defective p53 activity, which may be responsible for the oncogenic susceptibility of F3 cells observed after the introduction of H-Ras.
Susceptibility of F3 Cells to Oncogenic Stimulation
Lower p53-dependent transcriptional activity in F3 would be associated with tumorigenic potential as the result of a single oncogenic stimulation with H-Ras. To assess this, we transduced F3 cells with the oligodentrocyte lineage transcription factor Olig2 gene to generate oligodendrocytes (Fig. 7a) . Oligodendrocytes derived from F3 cells (F3.Olig2) were negative for both hNestin, as shown by immunocytochemistry (Fig. 7a, left panel) and Sox2, as determined via RT-PCR (Fig. 7a, right panel) ; however, CNPase, an oligodendrocyte marker, was highly positive in the F3.Olig2 cells (Fig. 7a, bottom panel) . In an effort to compare the oncogenic susceptibility, the colony formation of F3 cells was observed after the introduction of H-Ras. As demonstrated in Fig. 7b , the introduction of H-Ras to F3 cells induced the formation of colonies of cells with morphology typical of transformed cells, but this was not observed in the F3.Olig2 cells despite the stable expression (Fig. 7b) . In an effort to confirm the capability of H-Ras to transform either F3 or F3.Olig2 cells, identical numbers of cells after H-Ras introduction were seeded in soft agar. As anticipated, the introduction of H-Ras enabled colony formation by F3 cells but not by F3.Olig2 cells in the soft agar (Fig. 7c ). These results demonstrate that F3.Olig2 cells, the differentiated counterparts of F3 cells, are not susceptible to H-Ras-mediated oncogenic stimulation, although this is not the case in F3 cells.
Discussion
Thus far, the oncogenic transformation of glial cells, which were previously thought to be the only proliferating cells in the brain, has generally been recognized as the origin of glioma or glioblastoma multiforme. The results of a previous study showed that human glioma cells were generated from human astrocytes via serial oncogenic stimulation with SV40 T/t-Ag, hTERT, and H-ras v12G2 . It has also been broadly accepted that the malignant transfor- mation of human primary cells requires a complex oncogenic stimulation to overcome intrinsic tumor suppressive mechanisms, including the p53 and/or Rb tumor suppressors [41] . Therefore, the abrogation of p53 and/or Rb tumorsuppressive mechanisms in human primary cells must first be achieved to induce malignant transformation, as in cases of introduction of SV40 T/t-Ag or E6/E7 [2, 42] .
In this study, we demonstrated the successful transformation of human fetal NSCs via serial oncogenic stimulation only with v-myc and H-ras v12G (Fig. 1) . Considering the crucial functions of p53 in protecting cells against oncogenic transformation in a variety of cellular systems [43] , the lower p53 transcriptional activity of vmyc-expressing hfNSCs (F3 cells), although its underlying mechanisms remain unknown (Fig. 6) , may be responsible for the oncogenic transformation induced by a combination of v-myc and H-Ras. It is currently unclear as to the manner in which hfNSCs escape from apoptosis or cell cycle arrest when v-myc is introduced to effect cellular immortalization, as v-myc expression itself is sufficient to induce apoptosis or cellular senescence in a p53-dependent manner [44] [45] [46] . It is also worth noting that the oncogenic transformation induced by v-myc and H-Ras in hfNSCs did not occur when the hfNSCs lost neural stemness as the consequence of differentiation. After the differentiation of F3 cells into oligodendrocytes via the additional introduction of oligodendrocyte lineage transcription factor 2 (Olig2) as previously reported [47] and the consequent loss of neural stemness in those cells, the v-mycexpressing hfNSC cells were no longer susceptible to H-Rasinduced oncogenic transformations (Fig. 7) . These findings indicate that the expression of an unknown factor or factors responsible for H-Ras-induced oncogenic transformation may vary according to the neural stemness characteristics. This may account for the differing susceptibility to oncogenic transformation between differentiated glial cells and NSCs [2] . In regard to cancer stem cells, which have been detected in various types of solid cancers, it remains unclear as to whether the F3.Ras cells generated in the present study are identical to the brain cancer stem cells isolated from a variety of gliomas, although we collected some evidence to suggest that F3.Ras cells share known common characteristics of brain cancer stem cells, such as sphere formation (Fig. 2d) , ABCG2, ALDH1 expression, and EMT phenotypes (Fig. 3) . However, the glial tumor formed by xenografted F3.Ras cells exhibited clear heterogeneity, consisting of a small portion of hNestin-positive and a larger portion of human GFAP-positive cells (Fig. 4) . Considering that the tumor was composed of human-derived cells (Fig. 4e) , these results show that a larger volume of GFAPpositive cells may be derived from a small number of Nestin-positive F3.Ras cells. Additionally, only a small number of cells were actively proliferating, as determined via staining with either Ki-67 proliferation antigen or phospho-Histone H3 antibody; this result differs from those seen with tumors generated from human glioma cell lines (Fig. 4c and d and Supplemental figure 2) . These results are, however, consistent with the current cancer stem cell theory that a rare population of stem-like cancer cells can form heterogeneous cancers via asymmetric self-renewal, retaining rare populations of cancer stem cells. Thus, considering the shared properties of cancer stem cells, the F3.Ras cells should prove useful in further experiments, as a promising cellular platform for chemical drug-screening to find selective cancer stem cell inhibitors [48] .
Interestingly, the p53 phosphorylation (serine 15 and serine 46) occurring in the N-terminal region of p53, which protects the p53 protein against degradation and enhances p53 transcriptional activity [49, 50] , was detected following H-Ras introduction (Fig. 6a) . Although the observed increase in p53 phosphorylation is suggestive of increased p53 transcriptional activity, p53-dependent transcription in F3 cells after H-Ras introduction was shown to be suppressed relative to that observed in F3 cells (Fig. 6b, c and  d) . These results may indicate that different oncogenic susceptibility to H-Ras in F3 cells may result from defective p53 transcriptional activity and the consequent failure of tumor-suppressive mechanisms upon the introduction of HRas. We are currently attempting to assess which factor(s) (are) responsible for defective p53 transcriptional activity despite increases in phosphorylation. The alteration of acetylation status, another post-translational modification, the significance of which in the regulation of p53 transcriptional activity has been previously assessed [51] , may be responsible for the repression of p53 transcriptional activity under high phosphorylation status conditions. This interesting research subject will also be assessed in greater detail in the future.
Collectively, the findings of this study demonstrate that hfNSCs underwent tumorigenic transformation via the introduction of the serial genes, v-myc and H-Ras, forming heterogeneous glial tumors with some characteristics of cancer stem cells. The tumors formed by F3.Ras cells were identified as heterogeneous glial tumors, and harbored small numbers of Nestin-positive neural stem-like cells. The F3.Ras cells are expected to prove applicable not only to inquiries into the molecular mechanisms relevant to cancer formation from the neural stem cells, but also as a valuable cellular platform for the screening of selective drugs for cancer stem cells.
